ApoB Goal Cost-Effective in Primary Prevention

Strategy increased quality-adjusted life-years and showed favorable cost-effectiveness vs low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol goals

By
Kathryn Wighton
April 15, 2026
4 min

MDSpire News

Overview

ApoB-guided lipid-lowering therapy intensification in primary prevention yielded the greatest gains in quality-adjusted life-years (QALYs) and was cost-effective compared to LDL-C and non–HDL-C strategies. The incremental cost-effectiveness ratio (ICER) for apoB was $30,300 per QALY gained, with significant reductions in ASCVD events over a lifetime horizon.

Background

Lipid-lowering therapy is a cornerstone of primary prevention for atherosclerotic cardiovascular disease (ASCVD). Traditional targets include low-density lipoprotein cholesterol (LDL-C) and non–high-density lipoprotein cholesterol (non–HDL-C). Apolipoprotein B (apoB) has emerged as a potentially superior marker to guide treatment intensification. This study evaluated the cost-effectiveness and clinical outcomes of using apoB versus LDL-C and non–HDL-C targets in a large US primary prevention cohort.

Data Highlights

Strategy	ASCVD Events	QALYs Gained	Incremental Cost ($ millions)	ICER ($/QALY)	Treatment Intensification (%)
LDL-C <100 mg/dL	129,811	Reference	Reference	Reference	51
Non–HDL-C <118 mg/dL	129,194	965 additional	−2.1 (cost saving)	Dominant vs LDL-C	57
ApoB <78.7 mg/dL	128,176	1,324 additional vs non–HDL-C	40.2	30,300 vs non–HDL-C	64

Key Findings

ApoB-guided therapy prevented 1,018 more ASCVD events per 250,000 patients than non–HDL-C targeting.
ApoB strategy yielded the highest QALYs gained among the three lipid targets.
Incremental cost-effectiveness ratio for apoB vs non–HDL-C was $30,300 per QALY, well below common willingness-to-pay thresholds.
Treatment intensification rates were highest with apoB (64%) compared to non–HDL-C (57%) and LDL-C (51%).
Sex-specific ICERs showed apoB was cost-effective in both women ($35,900/QALY) and men ($26,600/QALY).
Higher costs with apoB strategy were mainly due to longer life expectancy and extended preventive treatment, not testing costs.

Clinical Implications

Using apoB as a target for lipid-lowering therapy intensification in primary prevention may optimize ASCVD risk reduction and improve population health outcomes cost-effectively. Clinicians should consider apoB measurement to guide treatment decisions, particularly given its association with greater QALY gains and acceptable cost-effectiveness. Adoption of apoB targets could lead to more appropriate intensification of statin and adjunctive therapies.

Conclusion

ApoB-guided lipid-lowering therapy intensification in primary prevention offers superior clinical benefits and is cost-effective compared to LDL-C and non–HDL-C targets. These findings support incorporating apoB measurement into guideline-based risk management strategies.